文献速递治疗药物监测与药物基因组学肝肾功能剂量调整

去乙基羟氯喹及CYP2D6多态性与系统性红斑狼疮低疾病活动度相关

Desethylhydroxychloroquine and CYP2D6 polymorphisms are associated with low disease activity in patients with systemic lupus erythematosus.
PubMed 文献 · Br J Clin Pharmacol · 2026-10-23

本研究纳入102例日本SLE患者,发现CYP2D6中间代谢型者DHCQ/HCQ比值及体重校正DHCQ浓度-剂量比均低于正常代谢型。调整后,血浆DHCQ每增加1个标准差,LDA的OR为1.80(95%CI 1.10-2.95),血浆DHCQ/HCQ比值OR为2.10(1.23-3.59)。HCQ浓度及CYP基因型与LDA无关。

要点

  • CYP2D6中间代谢型患者DHCQ暴露低于正常代谢型。
  • DHCQ浓度及DHCQ/HCQ比值与低疾病活动度正相关。
  • HCQ浓度及CYP基因型与低疾病活动度无关。

核心结论

  • CYP2D6基因型是DHCQ暴露的主要决定因素。
  • 较高的DHCQ浓度及DHCQ/HCQ比值与低疾病活动度相关,而HCQ浓度或基因型无关。
  • DHCQ可作为候选暴露标志物,需前瞻性验证。

研究设计与样本

  • 纳入接受HCQ至少6个月的日本SLE患者,共102例。
  • 采用LC-MS/MS测定全血和血浆HCQ、DHCQ及血浆4β-羟基胆固醇,并进行CYP2D6(*2、*5、*10)和CYP3A5(*3)基因分型。
  • 主要结局为低疾病活动度,定义为SLEDAI-2K≤4且口服糖皮质激素≤5 mg/日。
  • 暴露变量以连续变量(对数转换,每1个标准差)纳入多变量逻辑回归分析。

主要发现

  • 102例患者中36例(35.3%)达到低疾病活动度。
  • 23例(22.5%)CYP2D6中间代谢型者的DHCQ/HCQ比值及体重校正DHCQ浓度-剂量比均低于正常代谢型(全血和血浆两种基质)。
  • 调整后每1个标准差增加的OR:血浆DHCQ为1.80(95%CI 1.10-2.95),血浆DHCQ/HCQ比值为2.10(1.23-3.59),全血DHCQ为1.73(1.04-2.88),全血DHCQ/HCQ比值为2.36(1.32-4.23)。
  • HCQ浓度和CYP基因型与低疾病活动度无关联。
  • 判别能力中等(AUC 0.62-0.67;bootstrap下限0.50-0.56)。

关键数值与推荐

  • 低疾病活动度定义:SLEDAI-2K≤4且口服糖皮质激素≤5 mg/日。
  • CYP2D6中间代谢型者DHCQ/HCQ比值及体重校正DHCQ浓度-剂量比低于正常代谢型。
  • 血浆DHCQ每增加1个标准差,低疾病活动度OR为1.80(95%CI 1.10-2.95)。
  • 血浆DHCQ/HCQ比值每增加1个标准差,低疾病活动度OR为2.10(95%CI 1.23-3.59)。
  • 全血DHCQ每增加1个标准差,低疾病活动度OR为1.73(95%CI 1.04-2.88);全血DHCQ/HCQ比值OR为2.36(95%CI 1.32-4.23)。

临床怎么用

  • 对于接受HCQ治疗的SLE患者,可关注DHCQ暴露及DHCQ/HCQ比值作为潜在疾病活动度标志物。
  • CYP2D6中间代谢型患者DHCQ暴露较低,可能需关注其疾病控制情况。
  • 目前证据尚不支持常规监测HCQ浓度或基因型来预测低疾病活动度。

局限性

  • 判别能力中等(AUC 0.62-0.67;bootstrap下限0.50-0.56)。
  • cutoff-based分析为探索性,采用bootstrap重采样评估乐观度。
  • DHCQ作为暴露标志物需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Hydroxychloroquine (HCQ) is standard therapy for systemic lupus erythematosus (SLE), but the clinical relevance of its active metabolite, desethylhydroxychloroquine (DHCQ), remains unclear. We examined whether DHCQ exposure is more closely related to disease control than HCQ exposure in Japanese patients with SLE. METHODS: Patients receiving HCQ for at least 6 months were enrolled. Whole-blood and plasma HCQ and DHCQ, and plasma 4β-hydroxycholesterol (a CYP3A activity marker), were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and CYP2D6 (*2, *5, *10) and CYP3A5 (*3) were genotyped. The primary outcome was low disease activity (LDA), defined as SLEDAI-2K ≤ 4 with oral corticosteroids ≤5 mg/day. Exposures were analysed as continuous variables (log-transformed, per 1 SD) in multivariable logistic regression; cutoff-based analyses were exploratory, with optimism assessed by bootstrap resampling. RESULTS: Among 102 patients, 36 (35.3%) attained LDA. The 23 (22.5%) CYP2D6 intermediate metabolisers had lower DHCQ/HCQ ratios and weight-adjusted DHCQ concentration-to-dose ratios than normal metabolisers in both matrices. HCQ concentrations and CYP genotypes were not associated with LDA. Adjusted odds ratios per 1 SD increase were 1.80 (95% CI 1.10-2.95) for plasma DHCQ, 2.10 (1.23-3.59) for the plasma DHCQ/HCQ ratio, 1.73 (1.04-2.88) for whole-blood DHCQ and 2.36 (1.32-4.23) for the whole-blood DHCQ/HCQ ratio. Discrimination was modest (AUC 0.62-0.67; lower bootstrap limits 0.50-0.56). CONCLUSIONS: CYP2D6 genotype was the principal determinant of DHCQ exposure. Higher DHCQ concentrations and DHCQ/HCQ ratios, but not HCQ concentrations or genotypes, were associated with LDA, supporting DHCQ as a candidate exposure marker requiring prospective validation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Uematsu Y, Hirai K, Ichikawa T, et al. Desethylhydroxychloroquine and CYP2D6 polymorphisms are associated with low disease activity in patients with systemic lupus erythematosus. Br J Clin Pharmacol. 2026. PMID: 42924549. doi:10.1002/bcp.70893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。